Loading clinical trials...
Loading clinical trials...
A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN
Conditions
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
+5 more
Locations
96
United States
UAB Child Health Research Unit (CHRU)
Birmingham, Alabama, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
Advanced Research Center Inc.
Anaheim, California, United States
Kaiser Permanente
Los Angeles, California, United States
Kaiser Permanente Oakland
Oakland, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Start Date
September 23, 2022
Primary Completion Date
July 23, 2026
Completion Date
July 23, 2026
Last Updated
April 13, 2026
NCT06631287
NCT05101213
NCT04565665
NCT04978571
NCT06082518
NCT07221162
Lead Sponsor
BioNTech SE
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions